Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines

Molecular Pharmaceutics

Volumn 13, Issue 3, 2016, Pages 720-728

  Hill, Tanner K ^a   Davis, Amanda L ^b   Wheeler, Frances B ^b   Kelkar, Sneha S ^c   Freund, Erica C ^d   Lowther, W Todd ^b   Kridel, Steven J ^b   Mohs, Aaron M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d WAKE FOREST UNIVERSITY   (United States)

Author keywords

fatty acid synthase; hyaluronic acid; nanoparticle; Orlistat; self assembly; tetrahydrolipstatin

Indexed keywords

ADENOSINE TRIPHOSPHATE; HYALURONIC ACID; NANOPARTICLE; SELF ASSEMBLED MONOLAYER; TETRAHYDROLIPSTATIN; THIOL ESTER HYDROLASE; ENZYME INHIBITOR; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; LACTONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TURNOVER TIME; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; FEMALE; MITOCHONDRION; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL CULTURE;

APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG COMPOUNDING; ENZYME INHIBITORS; FATTY ACID SYNTHASES; FATTY ACID SYNTHESIS INHIBITORS; FEMALE; HUMANS; LACTONES; MALE; MITOCHONDRIA; NANOPARTICLES; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84960116176     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00447     Document Type: Article

References (40)

1. Menendez, J. A.; Lupu, R. Fatty Acid Synthase and the Lipogenic Phenotype in Cancer Pathogenesis Nat. Rev. Cancer 2007, 7 (10) 763-777 10.1038/nrc2222
2. Maier, T.; Jenni, S.; Ban, N. Architecture of Mammalian Fatty Acid Synthase at 4.5 Å Resolution Science 2006, 311 (5765) 1258-1262 10.1126/science.1123248
3. Kuhajda, F. P. Fatty Acid Synthase and Cancer: New Application of an Old Pathway Cancer Res. 2006, 66 (12) 5977-5980 10.1158/0008-5472.CAN-05-4673
4. Flavin, R.; Peluso, S.; Nguyen, P. L.; Loda, M. Fatty Acid Synthase as a Potential Therapeutic Target in Cancer Future Oncol. 2010, 6 (4) 551-562 10.2217/fon.10.11
5. Pandey, P. R.; Liu, W.; Xing, F.; Fukuda, K.; Watabe, K. Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS) Recent Pat. Anti-Cancer Drug Discovery 2012, 7 (2) 185-197 10.2174/157489212799972891
6. Alli, P. M.; Pinn, M. L.; Jaffee, E. M.; McFadden, J. M.; Kuhajda, F. P. Fatty Acid Synthase Inhibitors Are Chemopreventive for Mammary Cancer in Neu-N Transgenic Mice Oncogene 2005, 24 (1) 39-46 10.1038/sj.onc.1208174
7. Li, J.; Gorospe, M.; Chrest, F.; Kumaravel, T. Pharmacological Inhibition of Fatty Acid Synthase Activity Produces Both Cytostatic and Cytotoxic Effects Modulated by p53 Cancer Res. 2001, 61, 1493-1499
8. Lupu, R.; Menendez, J. A. Pharmacological Inhibitors of Fatty Acid Synthase (FASN) - Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents? Curr. Pharm. Biotechnol. 2006, 7 (6) 483-493 10.2174/138920106779116928
9. Pizer, E.; Thupari, J.; Han, W.; Pinn, M. Malonyl-Coenzyme-A Is a Potential Mediator of Cytotoxicity Induced by Fatty-Acid Synthase Inhibition in Human Breast Cancer Cells and Xenografts Cancer Res. 2000, 60, 213-218
10. Filippatos, T.; Derdemezis, C.; Gazi, I. Orlistat-Associated Adverse Effects and Drug Interactions- A Critical Review Drug Saf. 2008, 31 (1) 53-65 10.2165/00002018-200831010-00005
11. Pemble, C. W.; Johnson, L. C.; Kridel, S. J.; Lowther, W. T. Crystal Structure of the Thioesterase Domain of Human Fatty Acid Synthase Inhibited by Orlistat Nat. Struct. Mol. Biol. 2007, 14 (8) 704-709 10.1038/nsmb1265
12. Fako, V. E.; Zhang, J.-T.; Liu, J.-Y. Mechanism of Orlistat Hydrolysis by the Thioesterase of Human Fatty Acid Synthase ACS Catal. 2014, 4, 3444-3453 10.1021/cs500956m
13. Kridel, S. J.; Axelrod, F.; Rozenkrantz, N.; Smith, J. W. Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity Cancer Res. 2004, 64 (6) 2070-2075 10.1158/0008-5472.CAN-03-3645
14. Browne, C. D.; Hindmarsh, E. J.; Smith, J. W. Inhibition of Endothelial Cell Proliferation and Angiogenesis by Orlistat, a Fatty Acid Synthase Inhibitor FASEB J. 2006, 20 (12) 2027-2035 10.1096/fj.05-5404com
15. Grube, S.; Dünisch, P.; Freitag, D.; Klausnitzer, M.; Sakr, Y.; Walter, J.; Kalff, R.; Ewald, C. Overexpression of Fatty Acid Synthase in Human Gliomas Correlates with the WHO Tumor Grade and Inhibition with Orlistat Reduces Cell Viability and Triggers Apoptosis J. Neuro-Oncol. 2014, 118 (2) 277-287 10.1007/s11060-014-1452-z
16. Menendez, J. a; Vellon, L.; Lupu, R. Antitumoral Actions of the Anti-Obesity Drug Orlistat (XenicalTM) in Breast Cancer Cells: Blockade of Cell Cycle Progression, Promotion of Apoptotic Cell Death and PEA3-Mediated Transcriptional Repression of Her2/neu (erbB-2) Oncogene Ann. Oncol. 2005, 16 (8) 1253-1267 10.1093/annonc/mdi239
17. Chuang, H. Y.; Chang, Y. F.; Hwang, J. J. Antitumor Effect of Orlistat, a Fatty Acid Synthase Inhibitor, Is via Activation of Caspase-3 on Human Colorectal Carcinoma-Bearing Animal Biomed. Pharmacother. 2011, 65 (4) 286-292 10.1016/j.biopha.2011.02.016
18. Little, J. L.; Wheeler, F. B.; Fels, D. R.; Koumenis, C.; Kridel, S. J. Inhibition of Fatty Acid Synthase Induces Endoplasmic Reticulum Stress in Tumor Cells Cancer Res. 2007, 67 (3) 1262-1269 10.1158/0008-5472.CAN-06-1794
19. Dowling, S.; Cox, J.; Cenedella, R. J. Inhibition of Fatty Acid Synthase by Orlistat Accelerates Gastric Tumor Cell Apoptosis in Culture and Increases Survival Rates in Gastric Tumor Bearing Mice in Vivo Lipids 2009, 44 (6) 489-498 10.1007/s11745-009-3298-2
20. Agostini, M.; Almeida, L. Y.; Bastos, D. C.; Ortega, R. M.; Moreira, F. S.; Seguin, F.; Zecchin, K. G.; Raposo, H. F.; Oliveira, H. C. F.; Amoedo, N. D.; Salo, T.; Coletta, R. D.; Graner, E. The Fatty Acid Synthase Inhibitor Orlistat Reduces the Growth and Metastasis of Orthotopic Tongue Oral Squamous Cell Carcinomas Mol. Cancer Ther. 2014, 13 (3) 585-595 10.1158/1535-7163.MCT-12-1136
21. Seguin, F.; Carvalho, M. A.; Bastos, D. C.; Agostini, M.; Zecchin, K. G.; Alvarez-Flores, M. P.; Chudzinski-Tavassi, a M.; Coletta, R. D.; Graner, E. The Fatty Acid Synthase Inhibitor Orlistat Reduces Experimental Metastases and Angiogenesis in B16-F10 Melanomas Br. J. Cancer 2012, 107 (6) 977-987 10.1038/bjc.2012.355
22. Carvalho, M. A.; Zecchin, K. G.; Seguin, F.; Bastos, D. C.; Agostini, M.; Rangel, A. L. C. a; Veiga, S. S.; Raposo, H. F.; Oliveira, H. C. F.; Loda, M.; Coletta, R. D.; Graner, E. Fatty Acid Synthase Inhibition with Orlistat Promotes Apoptosis and Reduces Cell Growth and Lymph Node Metastasis in a Mouse Melanoma Model Int. J. Cancer 2008, 123 (11) 2557-2565 10.1002/ijc.23835
23. Orlistat: DB01083. http://www.drugbank.ca/drugs/DB01083.
24. Wishart, D. S.; Knox, C.; Guo, A. C.; Shrivastava, S.; Hassanali, M.; Stothard, P.; Chang, Z.; Woolsey, J. DrugBank: A Comprehensive Resource for in Silico Drug Discovery and Exploration Nucleic Acids Res. 2006, 34 (Database issue) D668-D672 10.1093/nar/gkj067
25. Zhi, J.; Melia, A. T.; Funk, C.; Viger-Chougnet, A.; Hopfgartner, G.; Lausecker, B.; Wang, K.; Fulton, J. S.; Gabriel, L.; Mulligan, T. E. Metabolic Profiles of Minimally Absorbed Orlistat in Obese/overweight Volunteers J. Clin. Pharmacol. 1996, 36 (11) 1006-1011 10.1177/009127009603601104
26. Hargittai, I.; Hargittai, M. Molecular Structure of Hyaluronan: An Introduction Struct. Chem. 2008, 19 (5) 697-717 10.1007/s11224-008-9370-3
27. Laurent, T.; Fraser, J. Hyaluronan FASEB J. 1992, 6, 2397-2404
28. Hill, T. K.; Abdulahad, A.; Kelkar, S. S.; Marini, F. C.; Long, T. E.; Provenzale, J. M.; Mohs, A. M. Indocyanine Green-Loaded Nanoparticles for Image-Guided Tumor Surgery Bioconjugate Chem. 2015, 26 (2) 294-303 10.1021/bc5005679
29. Cho, H.-J.; Yoon, H. Y.; Koo, H.; Ko, S.-H.; Shim, J.-S.; Lee, J.-H.; Kim, K.; Kwon, I. C.; Kim, D.-D. Self-Assembled Nanoparticles Based on Hyaluronic Acid-Ceramide (HA-CE) and Pluronic® for Tumor-Targeted Delivery of Docetaxel Biomaterials 2011, 32 (29) 7181-7190 10.1016/j.biomaterials.2011.06.028
30. Choi, K. Y.; Yoon, H. Y.; Kim, J.-H.; Bae, S. M.; Park, R.-W.; Kang, Y. M.; Kim, I.-S.; Kwon, I. C.; Choi, K.; Jeong, S. Y.; Kim, K.; Park, J. H. Smart Nanocarrier Based on PEGylated Hyaluronic Acid for Cancer Therapy ACS Nano 2011, 5 (11) 8591-8599 10.1021/nn202070n
31. Bennett, P. K.; Li, Y. T.; Edom, R.; Henion, J. Quantitative Determination of Orlistat (tetrahydrolipostatin, Ro 18-0647) in Human Plasma by High-Performance Liquid Chromatography Coupled with Ion Spray Tandem Mass Spectrometry J. Mass Spectrom. 1997, 32 (7) 739-749 10.1002/(SICI)1096-9888(199707)32:7<739::AID-JMS526>3.3.CO;2-3
32. Mohammadi, a.; Haririan, I.; Rezanour, N.; Ghiasi, L.; Walker, R. B. A Stability-Indicating High Performance Liquid Chromatographic Assay for the Determination of Orlistat in Capsules J. Chromatogr. A 2006, 1116 (1-2) 153-157 10.1016/j.chroma.2006.03.038
33. Souri, E.; Jalalizadeh, H.; Kebriaee-Zadeh, A.; Zadehvakili, B. HPLC Analysis of Orlistat and Its Application to Drug Quality Control Studies Chem. Pharm. Bull. 2007, 55 (2) 251-254 10.1248/cpb.55.251
34. Odens, H.; Lowther, T.; Kridel, S.; Watts, L.; Filipponi, L.; Schmitt, J. Inhibition of the Thioesterase Activity of Human Fatty Acid Synthase by 1,4- and 9,10-Diones Chem. Pharm. Bull. 2014, 62 (9) 933-936 10.1248/cpb.c13-00809
35. Purohit, V. C.; Richardson, R. D.; Smith, J. W.; Romo, D. Practical, Catalytic, Asymmetric Synthesis of Beta-Lactones via a Sequential Ketene Dimerization/hydrogenation Process: Inhibitors of the Thioesterase Domain of Fatty Acid Synthase J. Org. Chem. 2006, 71 (12) 4549-4558 10.1021/jo060392d
36. Hill, B. G.; Dranka, B. P.; Zou, L.; Chatham, J. C.; Darley-Usmar, V. M. Importance of the Bioenergetic Reserve Capacity in Response to Cardiomyocyte Stress Induced by 4-Hydroxynonenal Biochem. J. 2009, 424 (1) 99-107 10.1042/BJ20090934
37. Pallasch, C. P.; Schwamb, J.; Königs, S.; Schulz, a; Debey, S.; Kofler, D.; Schultze, J. L.; Hallek, M.; Ultsch, a; Wendtner, C.-M. Targeting Lipid Metabolism by the Lipoprotein Lipase Inhibitor Orlistat Results in Apoptosis of B-Cell Chronic Lymphocytic Leukemia Cells Leukemia 2008, 22 (3) 585-592 10.1038/sj.leu.2405058
38. Choi, K. Y.; Min, K. H.; Yoon, H. Y.; Kim, K.; Park, J. H.; Kwon, I. C.; Choi, K.; Jeong, S. Y. PEGylation of Hyaluronic Acid Nanoparticles Improves Tumor Targetability in Vivo Biomaterials 2011, 32 (7) 1880-1889 10.1016/j.biomaterials.2010.11.010
39. Bae, Y. H.; Park, K. Targeted Drug Delivery to Tumors: Myths, Reality and Possibility J. Controlled Release 2011, 153 (3) 198-205 10.1016/j.jconrel.2011.06.001
40. Petros, R. A.; DeSimone, J. M. Strategies in the Design of Nanoparticles for Therapeutic Applications Nat. Rev. Drug Discovery 2010, 9 (8) 615-627 10.1038/nrd2591